Research
Hormonal
Higher TSH levels within the normal reference range are positively associated with total cholesterol, triglycerides, and blood pressure.
If your TSH is on the higher end of the 'normal' range, it might be contributing to higher blood pressure and cholesterol, even if you don't have hypothyroidism. This suggests that 'normal' TSH might not be 'optimal' for everyone, especially regarding cardiovascular health.
GoodSupportsHIGH confidence
TSH related positively with total cholesterol levels (p<0.01), triglycerides and systolic and diastolic blood pressure (all p<0.001).
Why this rating
Large sample size, consistent with previous literature.
Source
Triiodothyronine and Free Thyroxine Levels are Differentially Associated with Metabolic Profile and Adiposity-Related Cardiovascular Risk Markers in Euthyroid Middle-Aged Subjects
Greet Roef et al. · Thyroid · 2013
DOI 10.1089/thy.2013.0314
cross_sectional · n=2315Cited 166×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In euthyroid middle-aged adults, higher free T3 levels and a higher FT3-to-FT4 ratio are positively associated with unfavorable metabolic profiles (higher BMI, waist circumference, triglycerides, blood pressure, fasting glucose, and lower HDL) and increased cardiovascular risk markers (IL-6, hs-CRP, pulse wave velocity).Good
- Lower Free T4 (FT4) levels within the euthyroid range are negatively associated with BMI, waist circumference, and triglycerides, and positively associated with HDL-cholesterol.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →